Sign up

Kynam Capital Management, LP

$1.8B assets · 32 holdings · Q2 2026 · Filed 14 AUG 2026

About Kynam Capital Management, LP’s 13F portfolio

Kynam Capital Management, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Kynam Capital Management, LP reported $1.8B across 32 US-listed positions (). Its largest position is CELLDEX THERAPEUTICS INC NEW (CLDX) at 11% of the reported book, and its ten biggest holdings make up 73% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$1.8B
Assets (13F)
#1,596
of 8,839 by size
32
Holdings
73%
Top-10 weight
17
Buys
15
Sells
Top holdings · Q2 2026
32 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: CLDX
CELLDEX THERAPEUTICS INC NEW
—
—
11%
5.3M$198.1M
2
NASDAQ: SNDX
SYNDAX PHARMACEUTICALS INC
—
—
9.7%
8.1M$176.0M
3
NASDAQ: PCVX
VAXCYTE INC
—
—
9.4%
2.9M$169.9M
4
NASDAQ: COGT
COGENT BIOSCIENCES INC
—
—
7.8%
3.7M$141.9M
5
NASDAQ: VERA
VERA THERAPEUTICS INC
—
—
6.9%
2.9M$124.0M
6
NASDAQ: VRDN
VIRIDIAN THERAPEUTICS INC
—
—
6.6%
6.5M$118.6M
7
NASDAQ: TVTX
TRAVERE THERAPEUTICS INC
—
—
6.3%
2.0M$113.6M
8
NASDAQ: BEAM
BEAM THERAPEUTICS INC
—
—
5.4%
2.8M$97.5M
9
NASDAQ: URGN
UROGEN PHARMA LTD
—
—
5.0%
2.4M$89.6M
10
NASDAQ: LEGN
LEGEND BIOTECH CORP
—
—
4.8%
3.0M$86.7M
11
NASDAQ: CTMX
CYTOMX THERAPEUTICS INC.
—
—
4.5%
21.7M$81.4M
12
NASDAQ: RLAY
RELAY THERAPEUTICS INC
—
—
3.4%
3.3M$61.7M
13
NASDAQ: CGEM
CULLINAN THERAPEUTICS INC
—
—
3.1%
3.1M$56.7M
14
NASDAQ: MBX
MBX BIOSCIENCES INC
—
—
2.9%
935K$51.6M
15
NASDAQ: IMCR
IMMUNOCORE HLDGS PLC
—
—
2.4%
1.4M$43.7M
16
NASDAQ: NRIX
NURIX THERAPEUTICS INC
—
—
1.6%
1.2M$29.0M
17
NASDAQ: STRO
SUTRO BIOPHARMA INC
—
—
1.6%
873K$29.0M
18
NASDAQ: BCRX
BIOCRYST PHARMACEUTICALS INC
—
—
1.4%
2.5M$25.2M
19
NASDAQ: PHVS
PHARVARIS N V
—
—
1.3%
662K$22.9M
20
NASDAQ: SMMT
SUMMIT THERAPEUTICS INC
—
—
1.0%
1.2M$17.5M
21
NASDAQ: PRLD
PRELUDE THERAPEUTICS INC
—
—
0.7%
2.4M$12.9M
22
NASDAQ: INSM
INSMED INC
—
—
0.6%
100K$10.7M
23
NASDAQ: BNR
BURNING ROCK BIOTECH LTD
—
—
0.6%
1.2M$10.5M
24
NASDAQ: GERN
GERON CORP
—
—
0.5%
6.8M$8.8M
25
NASDAQ: AMRN
AMARIN CORP PLC
—
—
0.5%
533K$8.5M

Showing 1–25 of 32 positions on this page reported in this 13F.

Sector allocation
  • Healthcare100%
Recent activity · vs 2026-03-31
Bought17
  • AddedVRDNVIRIDIAN THERAPEUTICS INC+176%$118.6M
  • AddedTVTXTRAVERE THERAPEUTICS INC+27.5%$113.6M
  • AddedURGNUROGEN PHARMA LTD+8.3%$89.6M
  • AddedLEGNLEGEND BIOTECH CORP+90.4%$86.7M
  • AddedCTMXCYTOMX THERAPEUTICS INC.+44.6%$81.4M
  • AddedRLAYRELAY THERAPEUTICS INC+132%$61.7M
  • AddedIMCRIMMUNOCORE HLDGS PLC+55.4%$43.7M
  • AddedPHVSPHARVARIS N V+3.3%$22.9M
  • NewSMMTSUMMIT THERAPEUTICS INC—$17.5M
  • AddedPRLDPRELUDE THERAPEUTICS INC+51.6%$12.9M
Sold15
  • ReducedCLDXCELLDEX THERAPEUTICS INC NEW−8.9%$198.1M
  • ReducedCOGTCOGENT BIOSCIENCES INC−9.2%$141.9M
  • ReducedVERAVERA THERAPEUTICS INC−15.0%$124.0M
  • ReducedBEAMBEAM THERAPEUTICS INC−22.9%$97.5M
  • ReducedBCRXBIOCRYST PHARMACEUTICALS INC−55.6%$25.2M
  • ReducedCADLCANDEL THERAPEUTICS INC−51.6%$996K
  • SoldAPLSAPELLIS PHARMACEUTICALS INC−100%—
  • SoldENGNENGENE HOLDINGS INC−100%—
  • SoldDSGNDESIGN THERAPEUTICS INC−100%—
  • SoldWVEWAVE LIFE SCIENCES LTD−100%—
5%+ Beneficial Ownership Stakes · 1 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
CLDX
Celldex Therapeutics, Inc.
13G9.8% · 2 classes6.5MFiled 15 MAY 2025

Showing all 1 disclosed stakes. 1 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Kynam Capital Management, LP’s 13F portfolio

Kynam Capital Management, LP’s $1.8B 13F book is spread across 32 reported positions and is highly concentrated — its ten largest positions alone are 73% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are CLDX, SNDX, PCVX, COGT and VERA, led by CELLDEX THERAPEUTICS INC NEW (CLDX) at 11% of the portfolio. The heaviest sector exposure is Healthcare (100%).

What Kynam Capital Management, LP changed last quarter

Between 2026-03-31 and Q2 2026, Kynam Capital Management, LP was roughly balanced between buying and selling: it opened 5 new positions and added to 12 more, while trimming 6 and closing 9 outright. Against a 32-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was VIRIDIAN THERAPEUTICS INC (VRDN), and its biggest reduction was CELLDEX THERAPEUTICS INC NEW (CLDX).

What a 13F does and doesn’t reveal

A 13F captures only Kynam Capital Management, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Kynam Capital Management, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Kynam Capital Management, LP's profile on this page is built directly from those filings.

How current is the 13F data on Kynam Capital Management, LP's page?

It reflects Kynam Capital Management, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Kynam Capital Management, LP files its next quarterly report, this page refreshes automatically.

Can I see Kynam Capital Management, LP's complete list of holdings?

This page highlights Kynam Capital Management, LP's largest positions rather than all 32 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Kynam Capital Management, LP's filings.

Does a 13F show everything Kynam Capital Management, LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Kynam Capital Management, LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Kynam Capital Management, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.